The Potential Roles of Galectin-3 in AKI and CKD

Overview

Journal Front Physiol

Date 2023 Mar 13

PMID 36909244

Authors

Fengyun Wang

Lixin Zhou

Amity Eliaz

Chang Hu

Xinhua Qiang

Li Ke

Glenn Chertow

Isaac Eliaz

Zhiyong Peng

Affiliations

Soon will be listed here.

Abstract

Acute kidney injury (AKI) is a common condition with high morbidity and mortality, and is associated with the development and progression of chronic kidney disease (CKD). The beta-galactoside binding protein galectin-3 (Gal3), with its proinflammatory and profibrotic properties, has been implicated in the development of both AKI and CKD. Serum Gal3 levels are elevated in patients with AKI and CKD, and elevated Gal3 is associated with progression of CKD. In addition, Gal3 is associated with the incidence of AKI among critically ill patients, and blocking Gal3 in murine models of sepsis and ischemia-reperfusion injury results in significantly lower AKI incidence and mortality. Here we review the role of Gal3 in the pathophysiology of AKI and CKD, as well as the therapeutic potential of targeting Gal3.

Citing Articles

Sepsis-Associated Acute Kidney Injury: What's New Regarding Its Diagnostics and Therapeutics?.

Kounatidis D, Tzivaki I, Daskalopoulou S, Daskou A, Adamou A, Rigatou A Diagnostics (Basel). 2025; 14(24.

PMID: 39767206 PMC: 11674886. DOI: 10.3390/diagnostics14242845.

Renal Fibrosis: SIRT1 Still of Value.

Wu H, Qiu Z, Wang L, Li W Biomedicines. 2024; 12(9).

PMID: 39335456 PMC: 11428497. DOI: 10.3390/biomedicines12091942.

Galectin-3 protects distal convoluted tubules in rhabdomyolysis-induced kidney injury.

Kulow V, Labes R, Czopek C, Rosenberger C, Fahling M Pflugers Arch. 2024; 476(10):1571-1585.

PMID: 39042141 PMC: 11381487. DOI: 10.1007/s00424-024-02987-0.

Association of serum galectin-3 levels with mortality and cardiovascular disease outcomes in hemodialysis patients: a systematic review and dose-response meta-analysis.

Bellos I, Marinaki S, Lagiou P, Benetou V Int Urol Nephrol. 2024; 56(8):2755-2767.

PMID: 38519721 PMC: 11266241. DOI: 10.1007/s11255-024-04026-4.

Galectin-3 Mediates Endotoxin Internalization and Caspase-4/11 Activation in Tubular Epithelials and Macrophages During Sepsis and Sepsis-Associated Acute Kidney Injury.

Wang F, Ye J, Zhu W, Ge R, Hu C, Qian Y Inflammation. 2023; 47(1):454-468.

PMID: 37979076 DOI: 10.1007/s10753-023-01928-w.

References

Hodeib H, Hagras M, Abdelhai D, Watany M, Selim A, Tawfik M . Galectin-3 as a prognostic biomarker for diabetic nephropathy. Diabetes Metab Syndr Obes. 2019; 12:325-331. PMC: 6422412. DOI: 10.2147/DMSO.S194410. View

Hsu B, Wang C, Lai Y, Tsai J . Serum Galectin-3 Level Is Positively Associated with Endothelial Dysfunction in Patients with Chronic Kidney Disease Stage 3 to 5. Toxins (Basel). 2021; 13(8). PMC: 8402460. DOI: 10.3390/toxins13080532. View

Almaani S, Prokopec S, Zhang J, Yu L, Avila-Casado C, Wither J . Rethinking Lupus Nephritis Classification on a Molecular Level. J Clin Med. 2019; 8(10). PMC: 6832959. DOI: 10.3390/jcm8101524. View

Sun H, Jiang H, Eliaz A, Kellum J, Peng Z, Eliaz I . Galectin-3 in septic acute kidney injury: a translational study. Crit Care. 2021; 25(1):109. PMC: 7977587. DOI: 10.1186/s13054-021-03538-0. View

Mueller T, Leitner I, Egger M, Haltmayer M, Dieplinger B . Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin Chim Acta. 2015; 445:155-60. DOI: 10.1016/j.cca.2015.03.033. View

Hoste E, Kellum J, Selby N, Zarbock A, Palevsky P, Bagshaw S . Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018; 14(10):607-625. DOI: 10.1038/s41581-018-0052-0. View

Saccon F, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A . Role of galectin-3 in autoimmune and non-autoimmune nephropathies. Autoimmun Rev. 2016; 16(1):34-47. DOI: 10.1016/j.autrev.2016.09.023. View

Ghorbani A, Bhambhani V, Christenson R, Meijers W, de Boer R, Levy D . Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes. J Am Coll Cardiol. 2018; 72(25):3246-3254. PMC: 6516745. DOI: 10.1016/j.jacc.2018.09.076. View

Ruan L, Yao X, Li W, Zhang L, Yang H, Sun J . Effect of galectin-3 in the pathogenesis of arteriovenous fistula stenosis formation. Ren Fail. 2021; 43(1):566-576. PMC: 7993384. DOI: 10.1080/0886022X.2021.1902822. View

10.

Chen S, Kuo P . The Role of Galectin-3 in the Kidneys. Int J Mol Sci. 2016; 17(4):565. PMC: 4849021. DOI: 10.3390/ijms17040565. View

11.

Ji F, Zhang S, Jiang X, Xu Y, Chen Z, Fan Y . Diagnostic and prognostic value of galectin-3, serum creatinine, and cystatin C in chronic kidney diseases. J Clin Lab Anal. 2016; 31(5). PMC: 6816969. DOI: 10.1002/jcla.22074. View

12.

Martinez-Martinez E, Ibarrola J, Fernandez-Celis A, Calvier L, Leroy C, Cachofeiro V . Galectin-3 pharmacological inhibition attenuates early renal damage in spontaneously hypertensive rats. J Hypertens. 2017; 36(2):368-376. DOI: 10.1097/HJH.0000000000001545. View

13.

Kim A, Ro H, Kim H, Chang J, Lee H, Chung W . Soluble ST2 and Galectin-3 as Predictors of Chronic Kidney Disease Progression and Outcomes. Am J Nephrol. 2021; 52(2):119-130. DOI: 10.1159/000513663. View

14.

Tuegel C, Katz R, Alam M, Bhat Z, Bellovich K, de Boer I . GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. Am J Kidney Dis. 2018; 72(4):519-528. PMC: 6153047. DOI: 10.1053/j.ajkd.2018.03.025. View

15.

Ou S, Tsai M, Chen H, Li F, Lee K, Tseng W . Urinary Galectin-3 as a Novel Biomarker for the Prediction of Renal Fibrosis and Kidney Disease Progression. Biomedicines. 2022; 10(3). PMC: 8945118. DOI: 10.3390/biomedicines10030585. View

16.

Li H, Yang S, Li J, Feng J . Galectin 3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity. Biosci Rep. 2018; 38(6). PMC: 6435560. DOI: 10.1042/BSR20181803. View

17.

Bertocchi A, Campanhole G, Wang P, Goncalves G, Damiao M, Cenedeze M . A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl Int. 2008; 21(10):999-1007. DOI: 10.1111/j.1432-2277.2008.00705.x. View

18.

Liu S, Wu Q, Zhang S, Wang Z, Liu H, Teng L . Serum Galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study. BMC Nephrol. 2022; 23(1):5. PMC: 8722353. DOI: 10.1186/s12882-021-02636-z. View

19.

Sun H, Peng J, Cai S, Nie Q, Li T, Kellum J . A translational study of Galectin-3 as an early biomarker and potential therapeutic target for ischemic-reperfusion induced acute kidney injury. J Crit Care. 2021; 65:192-199. DOI: 10.1016/j.jcrc.2021.06.013. View

20.

Wang J, Xiao W, Zhong Y, Li X, Du S, Xie P . Galectin-3 deficiency protects lipopolysaccharide-induced chondrocytes injury via regulation of TLR4 and PPAR-γ-mediated NF-κB signaling pathway. J Cell Biochem. 2018; 120(6):10195-10204. DOI: 10.1002/jcb.28304. View